摘要
目的头孢哌酮/舒巴坦联合米诺环素治疗多药耐药鲍氏不动杆菌(MDR-ABA)呼吸机相关性肺炎(VAP)的临床疗效。方法收集医院2008年11月-2010年3月使用头孢哌酮/舒巴坦联合米诺环素治疗MDR-ABA所致VAP患者临床资料,对其药敏、临床疗效和预后进行回顾性总结分析。结果 32例VAP患者MDR-ABA仅对头孢哌酮/舒巴坦和米诺环素保持高敏感率,对其余抗菌药物高度耐药,使用头孢哌酮/舒巴坦联合米诺环素治疗,临床总有效率68.8%,细菌清除率28.1%,死亡8例;年龄、APACHEⅡ和血浆脑钠肽是影响预后的独立危险因素(P<0.05)。结论 MDR-ABA引起的VAP,根据医院分离株的耐药特点,使用头孢哌酮/舒巴坦联合米诺环素治疗具有较好疗效。
OBJECTIVE To observe the efficacy of cefoperazone/sulbactam combined with minocycline in treatment of ventilator associated pneumonia（VAP） with multidrug-resistant Acinetobacter baumannii（MDR-ABA）.METHODS The data were retrospectively collected from patients with ventilator associated pneumonia with multidrug-resistant acinetobacter baumannii treated by cefoperazone/sulbactam combined with minocycline from Nov 2008 to Mar 2010.The drug susceptibility,clinical efficacy and outcomes were reviewed.RESULTS Bacterial susceptibility to cefoperazone/sulbactam,and minocycline were higher while the resistance to other antibiotics was higher.Cefoperazone/sulbactam puls minocycline showed good efficacy for patients with MDR-ABA VAP.The total clinical cure rate 68.8%.Bacterial eradication rate was 28.1%,8 cases were dead.Age,APACHEⅡand plasma B-type natriuretic peptide were independent factors for the prognosis（P0.05）.Eight patients were died.CONCLUSION This study suggests that cefoperazone/sulbactam combined with minocycline may be an effective treatment for VAP infections caused by MDR-ABA in hospitals.
出处
《中华医院感染学杂志》
CAS
CSCD
北大核心
2011年第3期554-556,共3页
Chinese Journal of Nosocomiology
